Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Guggenheim Analyst Says

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lifted by research analysts at Guggenheim from $200.00 to $222.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 33.10% from the stock’s current price.

Several other brokerages have also recently issued reports on NBIX. Piper Sandler upped their target price on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 25th. Wedbush boosted their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada upped their price objective on shares of Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, Canaccord Genuity Group lifted their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.29.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded down $18.71 during trading on Friday, reaching $166.79. 804,441 shares of the company’s stock were exchanged, compared to its average volume of 1,176,510. The company has a 50 day moving average price of $167.61 and a two-hundred day moving average price of $146.25. The stock has a market cap of $16.77 billion, a P/E ratio of 25.62, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Leslie V. Norwalk sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director owned 1,588 shares of the company’s stock, valued at $289,031.88. This trade represents a 44.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the transaction, the insider owned 54,729 shares in the company, valued at $9,829,328.40. This trade represents a 15.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 395,422 shares of company stock worth $62,448,693 over the last three months. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. grew its holdings in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth $28,000. Basecamp Wealth Advisors LLC boosted its position in shares of Neurocrine Biosciences by 582.9% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after purchasing an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth $33,000. Finally, Meeder Asset Management Inc. grew its stake in shares of Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after purchasing an additional 202 shares during the period. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported second-quarter revenue of $959 million, up approximately 39% year over year and above the roughly $891 million analyst consensus. Adjusted earnings were $2.85 per share, surpassing estimates ranging from $1.66 to $2.26 and rising sharply from the prior year. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: The company raised 2026 net product-sales guidance for INGREZZA, its lead tardive-dyskinesia treatment, to $2.825 billion-$2.875 billion. INGREZZA sales increased 15% year over year to $716 million, while CRENESSITY contributed $184 million and newly acquired VYKAT XR generated $54 million after the Soleno Therapeutics acquisition closed in May. Neurocrine Biosciences Q2 Revenue Rises 39%
• Positive Sentiment: Analyst sentiment remains favorable, with several firms recently raising price targets between $195 and $221 and the shares carrying a consensus “Moderate Buy” rating. Neurocrine Biosciences Analyst and Trading Information
• Neutral Sentiment: Neurocrine ended the quarter with approximately $482 million in cash, cash equivalents and marketable securities. However, the quarter includes only a partial contribution from VYKAT XR following the Soleno acquisition, making integration and future product uptake important factors for investors.
• Negative Sentiment: Director Leslie Norwalk sold 1,250 shares worth approximately $227,500, reducing her ownership by 44%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which lessens its significance, but broader disclosures show numerous insider sales and no reported open-market insider purchases in the past six months. Neurocrine Director Stock Sale

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.